India’s pharmaceutical logistics market is projected to grow from $19.35 billion in 2026 to $25.35 billion by 2031, a 5.55% CAGR, with the cold-chain segment growing faster at 7.55%. The headlines belong to temperature-controlled trunk routes and biologics. But the layer where hundreds of regional logistics companies actually earn revenue — the last mile — has a structure that most pitch decks in this sector quietly misrepresent.

The Data

Indian pharma distribution runs through a specific intermediary architecture. A typical national pharma brand operates through 25–30 carrying and forwarding agents (CFAs), roughly one per major state, supplying 1,500–3,000 stockists nationally. The CFA holds the manufacturer’s stock — ownership stays with the brand, and the agent earns a service fee for storage, dispatch, and compliance handling, including Schedule H paperwork, batch tracking, and expiry management. Choosing between C&F operations, consignee agents, and channel partners is itself a distribution-model decision pharma companies weigh explicitly.

This architecture splits the logistics opportunity in two. Trunk movement — factory to CFA, including the 2°C–8°C cold chain — is contracted directly by pharma majors with national players, inside a broader Indian cold-chain logistics market projected at $24.85 billion in 2026. The last mile — CFA to stockist to chemist — is fragmented across regional couriers. Our sector research indicates the two layers differ by roughly two orders of magnitude in account value: a direct pharma-major trunk relationship is a crore-class account, while last-mile CFA accounts typically run at a few lakh rupees per year within a ~30 km service radius — an editorial estimate from our own assessment work, not a published statistic.

Two things follow from that structure. First, when a regional courier claims a high “pharma” revenue share, that revenue is usually many small CFA last-mile accounts, not principal contracts — a materially different revenue quality. Second, purchasing at this layer is won on quality systems rather than price: documentation, traceability, deviation reporting, audit-readiness. The buyer who matters is the pharma company’s quality head, not procurement.

Why It Matters

For operators, the realistic ladder up the value chain is not cryogenic or biologics logistics — that end is capex-heavy and occupied by national players. It is single-window aggregation: consolidating all of one pharma principal’s CFA last-mile movement in a state under uniform SOPs with end-to-end visibility. For anyone evaluating logistics deals, margin claims deserve bottom-up scrutiny. Industry estimates put healthy regional courier profitability in the mid-single digits; projections of 8–10% EBITDA need clean-sheet, per-kilometre costing proof, not narrative. And delivery-performance claims — “93% on-time” — are meaningless without the baseline promise per lane.

The Charaka View

We treat “pharma revenue share” as a claim requiring decomposition, not a positive signal by itself. In our own assessment work on Indian regional couriers, the pattern that separated genuine pharma capability from label-deep pharma exposure was never the revenue line — it was whether the company had institutionalised quality systems the sector’s actual buyers audit for. The margin-benchmark and value-chain observations above are editorial judgment drawn from our sector research, not published statistics; the market sizing and distribution architecture are independently sourced. In a sector growing at 5.5% against India’s much noisier logistics narratives, the durable wedge is boring: paperwork, done institutionally.

This analysis draws on Mordor Intelligence’s India pharmaceutical logistics report, Mordor Intelligence’s India cold chain logistics report, SalesPort’s CFA distribution explainer, and Sarjen’s pharma distribution model analysis. Human editorial oversight applied.

This analysis is informational and does not constitute investment advice, a research report, or a recommendation to buy, sell, or hold any security.

Charaka Notes by Manthan Intelligence. Subscribe